California Healthline May 7, 2024
Arthur Allen

When doctors began using the drug sotorasib in 2021 with high expectations for its innovative approach to attacking lung cancer, retired medical technician Don Crosslin was an early beneficiary. Crosslin started the drug that July. His tumors shrank, then stabilized.

But while the drug has helped keep him alive, its side effects have gradually narrowed the confines of his life, said Crosslin, 76, who lives in Ocala, Florida: “My appetite has been minimal. I’m very weak. I walk my dogs and get around a bit, but I haven’t been able to golf since last July.”

He wonders whether he’d do better on a lower dose, “but I do what my oncologist tells me to do,” Crosslin said. Every day, he...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
How To Prevent Alzheimer’s Disease: A Case For Vaccines
Obesity drugs could bankrupt US healthcare, says Sanders
First Wave BioPharma comes ashore with new name as it prepares for phase 3 trial
US Pharma and Biotech Summit 2024: A Biotech Industry Overview
AstraZeneca antibody reduced Covid-19 risk in immunocompromised

Share This Article